|
|
Volumn 102, Issue 16, 2010, Pages 1217-1218
|
|
Adaptive clinical trial design: has its time come?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
B RAF KINASE;
BRAF PROTEIN, HUMAN;
CCND1 PROTEIN, HUMAN;
CYCLIN D1;
EPIDERMAL GROWTH FACTOR RECEPTOR;
KRAS PROTEIN, HUMAN;
ONCOPROTEIN;
RAS PROTEIN;
RETINOID X RECEPTOR;
TUMOR MARKER;
VASCULOTROPIN A;
BREAST TUMOR;
CLINICAL TRIAL;
FEMALE;
GENETICS;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
METABOLISM;
METHODOLOGY;
MUTATION;
NEOPLASM;
NOTE;
STANDARD;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS AS TOPIC;
CYCLIN D1;
FEMALE;
HUMANS;
LUNG NEOPLASMS;
MUTATION;
NEOPLASMS;
PROTO-ONCOGENE PROTEINS;
PROTO-ONCOGENE PROTEINS B-RAF;
RAS PROTEINS;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
RESEARCH DESIGN;
RETINOID X RECEPTORS;
TUMOR MARKERS, BIOLOGICAL;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 77956088537
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djq319 Document Type: Note |
|
Times cited : (14)
|
|
References (0)
|
